Boundless Bio Announces Pipeline and Leadership Updates
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI …